Tessa Therapeutics’ TT11 gains stronger positioning to enter the Hodgkin’s lymphoma market

GlobalData anticipates Tessa Therapeutics to apply for regulatory approval in 2022 following the completion of its Phase II trial. Credit: Shutterstock.



  • Tessa Therapeutics